Details of the Drug Combination

General Information of Drug Combination (ID: DCO7S95)

Drug Combination Name
Eribulin GDC-0068
Indication
Disease Entry Status REF
Triple Negative Breast Cancer Phase 2 [1]
Component Drugs Eribulin   DM1DX4Q GDC-0068   DMWBZJD
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Eribulin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Liposarcoma 2B59 Approved [3]
Eribulin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [8]
------------------------------------------------------------------------------------
Eribulin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Indication(s) of GDC-0068
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [4]
Colorectal cancer 2B91.Z Phase 3 [4]
Prostate cancer 2C82.0 Phase 3 [5]
Gastric adenocarcinoma 2B72 Phase 2 [6]
Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
GDC-0068 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
GDC-0068 Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [10]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [10]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Affects Response To Substance [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04464174) Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
3 Eribulin FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Roche.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031868)
8 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
9 Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
10 PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.